In a report released today, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Cassava Sciences (SAVA – Research Report), with a price target of $28.00. The company’s shares closed yesterday at $25.40.
Mamtani covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Agenus, and Arrowhead Pharmaceuticals. According to TipRanks, Mamtani has an average return of -8.9% and a 33.80% success rate on recommended stocks.
Cassava Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $84.00.
See the top stocks recommended by analysts >>
Based on Cassava Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $19.13 million. In comparison, last year the company had a GAAP net loss of $14.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Read More on SAVA:
- Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
- Cassava Sciences announces 2023 scientific goals
- Cassava Sciences reports Q4 EPS (47c), consensus (56c)
- Cassava Sciences provides enrollment update for Phase 3 studies of simufilam
- Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
